Search

Your search keyword '"Rodriguez-Bano J."' showing total 148 results
Start Over Author "Rodriguez-Bano J."
148 results on '"Rodriguez-Bano J."'

1. Perpetual Observational Studies: New strategies to support efficient implementation of observational studies and randomized trials in the infectious diseases arena

Author

Hassoun-Kheir, N., van Werkhoven, C. H., Dunning, J., Jaenisch, T., van Beek, J., Bielicki, J., Butler, C., Francois, B., Harbarth, S., Padilla, A. C. Hernandez, Horby, P., Koopmans, M., Lee, J., Rodriguez-Baño, J., Tacconelli, E., Themistocleous, Y., van der Velden, A. W., Bonten, M., Goossens, H., and de Kraker, M. E. A.

Subjects
Statistics - Methodology
Abstract

The increasing threat of emerging infectious diseases and antimicrobial resistance requires more efficient, high-quality research. Perpetual Observational Studies (POS) nested within a clinical research network can improve planning, quality and efficiency of interventional and observational studies, although real-life benefits and challenges need to be assessed. Ecraid (European Clinical Research Alliance on Infectious Diseases) has initiated POS and will monitor the impact for five specific infectious syndromes., Comment: 16 pages, 2 tables

Published
2022
Full Text
View/download PDF

2. Incidence, associated disease burden and healthcare utilization due to Staphylococcus aureus prosthetic joint infection in European hospitals: the COMBACTE-NET ARTHR-IS multi-centre study

Author

Espíndola, R., Vella, V., Benito, N., Mur, I., Tedeschi, S., Zamparini, E., Hendriks, J.G.E., Sorlí, L., Murillo, O., Soldevila, L., Scarborough, M., Scarborough, C., Kluytmans, J., Ferrari, M.C., Pletz, M.W., McNamara, I., Escudero-Sanchez, R., Arvieux, C., Batailler, C., Dauchy, F.-A., Liu, W.-Y., Lora-Tamayo, J., Praena, J., Ustianowski, A., Cinconze, E., Pellegrini, M., Bagnoli, F., Rodríguez-Baño, J., and del-Toro-López, M.-D.

Published
2023
Full Text
View/download PDF

3. Outcomes of the PIRASOA programme, an antimicrobial stewardship programme implemented in hospitals of the Public Health System of Andalusia, Spain: an ecologic study of time-trend analysis

Author

Rodríguez-Baño, J., Pérez-Moreno, M.A., Peñalva, G., Garnacho-Montero, J., Pinto, C., Salcedo, I., Fernández-Urrusuno, R., Neth, O., Gil-Navarro, M.V., Pérez-Milena, A., Sierra, R., Estella, Á., Lupión, C., Irastorza, A., Márquez, J.L., Pascual, Á., Rojo-Martín, M.D., Pérez-Lozano, M.J., Valencia-Martín, R., and Cisneros, J.M.

Published
2020
Full Text
View/download PDF

10. Rhodomyrtone decreases Staphylococcus aureus SigB activity during exponentially growing phase and inhibits haemolytic activity within membrane vesicles

Author

Jover, A., Barcenilla, F., García, M., Pujol, M., Gasch, O., Domínguez, M.A., Camoez, M., Dueñas, C., Ojeda, E., Martínez, J.A., Marco, F., Chaves, F., Lagarde, M., López-Medrano, F., Montejo, J.M., Bereciertua, E., Hernández, J.L., von Wichmann, M.Á., Goenaga, A., García-Arenzana, J.M., Padilla, B., Padilla, C., Cercenado, E., García-Prado, G., Tapiol, J., Horcajada, J.P., Montero, M., Salvadó, M., Arnáiz, A., Fernández, C., Calbo, E., Xercavins, M., Granados, A., Fontanals, D., Pintado, V., Loza, E., Torre-Cisneros, J., Lara, R., Rodríguez-López, F., Natera, C., Blanco, J.R., Olarte, I., Benito, N., Mirelis, B., Murillas, J., Ruiz de Gopegui, E., Espejo, H., Morera, M.A., Rodríguez-Baño, J., López-Cortés, L.E., Pascual, A., Martín, C., Lepe, J.A., Molina, J., Sordé, R., Almirante, B., Larrosa, N., Mitsuwan, Watcharapong, Jiménez-Munguía, Irene, Visutthi, Monton, Sianglum, Wipawadee, Rodríguez-Ortega, Manuel J., and Voravuthikunchai, Supayang P.

Published
2019
Full Text
View/download PDF

13. ESCMID generic competencies in antimicrobial prescribing and stewardship: towards a European consensus

Author

Ashiru-Oredope, D., Barcs, I., Blix, H.S., Buyle, F., Chowers, M., Čižman, M., Cookson, B., Del Pozo, J.L., Deptula, A., Dumpis, U., Florea, D., van de Garde, E., Geffen, Y., Giske, C.G., Grau, S., Hajdú, E., Hell, M., Hondo, Ł., Hussein, K., Huttner, B., Kern, W., Kernéis, S., Knepper, V., Kofteridis, D., Kostyanev, T., Kuijper, E., Lebanova, H., Lewis, R., Cordina, C.M., Matulionyte, R., Maurer, F., Messiaen, P., Miciuleviciene, J., Mrhar, A., Nabuurs-Franssen, M., Naesens, R., Oxacelay, C., Pagani, L., Paño-Pardo, J.R., Paul, M., Petrikkos, G., Pluess-Suard, C., Popescu, G.A., Porsche, U., Prins, J., Pulcini, C., Rello, J., Rodríguez-Baño, J., Rossolini, G.M., Salzberger, B., Seme, K., Simonsen, G.S., Sînziana, M., Skovgaard, S., Smith, I., Sönsken, U., Soriano, A., Sviestiņa, I., Szilagyi, E., Tängdén, T., Tattevin, P., Tsioutis, C., Vilde, A., Wanke-Rytt, M., Wechsler-Fördös, A., Zarb, P., Dyar, O.J., Beović, B., Tacconelli, E., and Hulscher, M.

Published
2019
Full Text
View/download PDF

15. Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals

Author

Abbo, L., Abgueguen, P., Almirante, B., Azzini, A.M., Bani-Sadr, F., Bassetti, M., Ben-Ami, R., Beović, B., Béraud, G., Botelho-Nevers, E., Bou, G., Boutoille, D., Cabié, A., Cacopardo, B., Cascio, A., Cassir, N., Castelli, F., Cecala, M., Charmillon, A., Chirouze, C., Cisneros, J.M., Colmenero, J.D., Coppola, N., Corcione, S., Daikos, G.L., Dalla Gasperina, D., De la Calle Cabrera, C., Delobel, P., Di Caprio, D., Durante Mangoni, E., Dupon, M., Ettahar, N., Falagas, M.E., Falcone, M., Fariñas, M.C., Faure, E., Forestier, E., Foti, G., Gallagher, J., Gattuso, G., Gendrin, V., Gentile, I., Giacobbe, D.R., Gogos, C.A., Grandiere Perez, L., Hansmann, Y., Horcajada, J.P., Iacobello, C., Jacob, J.T., Justo, J.A., Kernéis, S., Komnos, A., Kotnik Kevorkijan, B., Lebeaux, D., Le Berre, R., Lechiche, C., Le Moxing, V., Lescure, F.X., Libanore, M., Martinot, M., Merino de Lucas, E., Mondain, V., Mondello, P., Montejo, M., Mootien, J., Muñoz, P., Nir-Paz, R., Pan, A., Paño-Pardo, J.R., Patel, G., Paul, M., Pérez Rodríguez, M.T., Piroth, L., Pogue, J., Potoski, B.A., Pourcher, V., Pyrpasopoulou, A., Rahav, G., Rizzi, M., Rodríguez-Baño, J., Salavert, M., Scheetz, M., Sims, M., Spahija, G., Stefani, S., Stefos, A., Tamma, P.D., Tattevin, P., Tedesco, A., Torre-Cisneros, J., Tripolitsioti, P., Tsiodras, S., Uomo, G., Verdon, R., Viale, P., Vitrat, V., Weinberger, M., Wiener-Well, Y., Papst, L., Pulcini, C., Durante-Mangoni, E., Kaye, K.S., and Raka, L.

Published
2018
Full Text
View/download PDF

18. The methodology of surveillance for antimicrobial resistance and healthcare-associated infections in Europe (SUSPIRE): a systematic review of publicly available information

Author

Burkert, F., Carrara, E., von Cube, M., Drgona, L., Gilchrist, K., Goossens, H., Harbarth, S., Hequet, D., Jafri, H., Kahlmeter, G., Kuster, S., Luxemburger, C., McCarthy, M., Niks, M., Oualim, A., Poljak, M., Sandulescu, O., Schweiger, A., Vuong, C., Wiegand, I., Widmer, A., Witschi, A.T., Zanetti, G., Zingg, W., Núñez-Núñez, M., Navarro, M.D., Palomo, V., Rajendran, N.B., del Toro, M.D., Voss, A., Sharland, M., Sifakis, F., Tacconelli, E., and Rodríguez-Baño, J.

Published
2018
Full Text
View/download PDF

20. European survey on principles of prudent antibiotic prescribing teaching in undergraduate students

Author

Gyssens, I.C., Jacobs, F., Peetermans, W., Francetić, I., Vlahović-Palčevski, V., Frimodt-Mǿller, N., Høiby, N., Kilian, M., Ader, F., Cazorla, C., Etienne, M., Pulcini, C., Fätkenheuer, G., Kern, W.V., Pletz, M.W., Salzberger, B., Cacopardo, B., Mikulska, M., Mussini, C., Orlando, G., Stefani, S., Lowe, S.H., Nouwen, J.L., Afset, J.E., Bergh, K., Müller, F., Simonsen, G.S., Carevic, B., Horvat, O., Jankovic, S., Beović, B., Gorisek, J.R., Canton, R., Fariñas, M.C., Gudiol, F., Paño Pardo, J.R., Rodríguez Baño, J., Harbarth, S., Zanetti, G., Barlow, G., Brown, N., Healy, B., Nathwani, D., Wencker, F., Frimodt-Møller, N., and Rodríguez-Baño, J.

Published
2015
Full Text
View/download PDF

21. Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition

Author

Harris, P.N.A., McNamara, J.F., Lye, D.C., Davis, J.S., Bernard, L., Cheng, A.C., Doi, Y., Fowler, V.G., Jr., Kaye, K.S., Leibovici, L., Lipman, J., Llewelyn, M.J., Munoz-Price, S., Paul, M., Peleg, A.Y., Rodríguez-Baño, J., Rogers, B.A., Seifert, H., Thamlikitkul, V., Thwaites, G., Tong, S.Y.C., Turnidge, J., Utili, R., Webb, S.A.R., and Paterson, D.L.

Published
2017
Full Text
View/download PDF

25. Epidemiologic changes in bloodstream infections in Andalucía (Spain) during the last decade

Author

Martínez Pérez-Crespo, P.M., López-Cortés, L.E., Retamar-Gentil, P., García, J.F. Lanz, Vinuesa García, D., León, E., Calvo, J.M. Sánchez, Galán-Sánchez, F., Natera Kindelan, C., del Arco Jiménez, A., Sánchez-Porto, A., Herrero Rodríguez, C., Becerril Carral, B., Molina, I.M. Reche, Iglesias, J.M. Reguera, Pérez Camacho, I., Guzman García, M., López-Hernández, I., and Rodríguez-Baño, J.

Published
2021
Full Text
View/download PDF

32. Pseudomonas aeruginosa Community-Onset Bloodstream Infections: Characterization, Diagnostic Predictors, and Predictive Score Development-Results from the PRO-BAC Cohort

Author

Perez-Crespo P, Rojas A, Lanz-Garcia J, Retamar-Gentil P, Reguera-Iglesias J, Lima-Rodriguez O, Jimenez A, Suarez J, Jover-Saenz A, Aguirre J, Jimenez E, Canton-Bulnes M, Lafont P, Castillo C, Blanco J, Pedragosa J, Boix-Palop L, Carral B, Bahamonde-Carrasco A, Ciordia T, Kindelan C, Molina I, Rodriguez C, Camacho I, Garcia D, Galan-Sanchez F, Amat A, de Lucas E, Sanchez-Porto A, Garcia M, Lopez-Hernandez I, Rodriguez-Bano J, and Lopez-Cortes L

Subjects
bacteraemia, Pseudomonas aeruginosa, bloodstream infection, epidemiology, community-onset
Abstract

Community-onset bloodstream infections (CO-BSI) caused by gram-negative bacilli are common and associated with significant mortality; those caused by Pseudomonas aeruginosa are associated with worse prognosis and higher rates of inadequateempirical antibiotic treatment. The aims of this study were to describe the characteristics of patients with CO-BSI caused by P. aeruginosa, to identify predictors, and to develop a predictive score for P. aeruginosa CO-BSI. Materials/methods: PROBAC is a prospective cohort including patients >14 years with BSI from 26 Spanish hospitals between October 2016 and May 2017. Patients with monomicrobial P. aeruginosa CO-BSI and monomicrobial Enterobacterales CO-BSI were included. Variables of interest were collected. Independent predictors of Pseudomonas aeruginosa CO-BSI were identified by logistic regression and a prediction score was developed. Results: A total of 78patients with P. aeruginosa CO-BSI and 2572 with Enterobacterales CO-BSI were included. Patients with P. aeruginosa had a median age of 70 years (IQR 60-79), 68.8% were male, median Charlson score was 5 (IQR 3-7), and 30-daymortality was 18.5%. Multivariate analysis identified the following predictors of CO-BSI-PA [adjusted OR (95% CI)]: male gender [1.89 (1.14-3.12)], haematological malignancy [2.45 (1.20-4.99)], obstructive uropathy [2.86 (1.13-3.02)], source of infection other than urinary tract, biliary tract or intra-abdominal [6.69 (4.10-10.92)] and healthcare-associated BSI [1.85 (1.13-3.02)]. Anindex predictive of CO-BSI-PA was developed; scores >= 3.5 showed a negative predictive value of 89% and an area under the receiver operator curve (ROC) of 0.66. Conclusions: We did not find a good predictive score of P. aeruginosa CO-BSI due to its relatively low incidence in the overall population. Our model includes variables that are easy to collect in real clinical practice and could be useful to detect patients with very low risk of P. aeruginosa CO-BSI.

Published
2022

33. Early Stepdown From Echinocandin to Fluconazole Treatment in Candidemia: A Post Hoc Analysis of Three Cohort Studies (vol 8, ofab250, 2021)

Author

Moreno-Garcia, E., Puerta-Alcalde, P., Gariup, G., Fernandez-Ruiz, M., Lopez Cortes, L. E., Cuervo, G., Salavert, M., Merino, P., Machado, M., Guinea, J., Garcia-Rodriguez, J., Garnacho-Montero, J., Cardozo, C., Peman, J., Montejo, M., Fortun, J., Almirante, B., Castro, C., Rodriguez-Bano, J., Aguado, J. M., Martinez, J. A., Carratala, J., Soriano, A., and Garcia-Vidal, C.

Abstract

[This corrects the article DOI: 10.1093/ofid/ofab250.].

Published
2022

34. A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients

Author

Campoli, C., Siccardi, G., Ambretti, S., Stallmach, A., Venditti, M., Lucidi, C., Ludovisi, S., De Cueto, M., Navarro, M.D., Lopez Cortes, E., Bouza, E., Valerio, M., Eworo, A., Losito, R., Senzolo, M., Nadal, E., Ottobrelli, A., Varguvic, M., Badia, C., Borgia, G., Gentile, I., Buonomo, A.R., Boumis, E., Beteta-Lopez, A., Rianda, A., Taliani, G., Grieco, S., Bartoletti, M., Giannella, M., Lewis, R., Caraceni, P., Tedeschi, S., Paul, M., Schramm, C., Bruns, T., Merli, M., Cobos-Trigueros, N., Seminari, E., Retamar, P., Muñoz, P., Tumbarello, M., Burra, P., Torrani Cerenzia, M., Barsic, B., Calbo, E., Maraolo, A.E., Petrosillo, N., Galan-Ladero, M.A., D'Offizi, G., Bar Sinai, N., Rodríguez-Baño, J., Verucchi, G., Bernardi, M., and Viale, P.

Published
2018
Full Text
View/download PDF

37. Propensity Score and Desirability of Outcome Ranking Analysis of Ertapenem for Treatment of Nonsevere Bacteremic Urinary Tract Infections Due to Extended-Spectrum-Beta-Lactamase-Producing Enterobacterales in Kidney Transplant Recipients

Author

Gutierrez-Gutierrez, B., Perez-Nadales, E., Perez-Galera, S., Fernandez-Ruiz, M., Carratala, J., Oriol, I., Cordero, E., Lepe, J. A., Tan, B. H., Corbella, L., Paul, M., Natera, A. M., David, M. D., Montejo, M., Iyer, R. N., Pierrotti, L. C., Merino, E., Steinke, S. M., Rana, M. M., Munoz, P., Mularoni, A., van Delden, C., Grossi, P. A., Seminari, E. M., Gunseren, F., Lease, E. D., Roilides, E., Fortun, J., Arslan, H., Coussement, J., Tufan, Z. K., Pilmis, B., Rizzi, M., Loeches, B., Eriksson, B. M., Abdala, E., Soldani, F., Lowman, W., Clemente, W. T., Bodro, M., Farinas, M. C., Kazak, E., Martinez-Martinez, L., Aguado, J. M., Torre-Cisneros, J., Pascual, A., Rodriguez-Bano, J., Sabe, N., Camoez, M., Martin-Gandul, C., Bernal, G., Kee, T. Y. S., Lopez-Medrano, F., Juan, R. S., Koppel, F., Bar-Sinai, N., Caston, J. J., Cano, A., Gracia-Ahufinger, I., Rodriguez, R., Lopez-Soria, L., Azurmendi, M., Pinheiro, M., Freire, M., Banks, I., Lopes, F., David-Neto, E., Balibrea, N., Franco, A., Avery, R., Ostrander, D., Minero, M. V., Carrillo, C. S., Rodriguez-Ferrero, M. L., Monaco, F., Campanella, M., Mueller, N. J., Manuel, O., Khanna, N., Rovelli, C., Balsamo, M. L., Colombo, A., Leoni, C., Pyrpasopoulou, A., Mouloudi, E., Iosifidis, E., Martin-Davila, P., Gioia, F., Escudero, R., Demirkaya, M. H., Dewispelaere, L., Kalem, A. K., Hasanoglu, I., Guner, R., Lortholary, O., Scemla, A., Calvi, E. G., Gervasi, E., Binda, F., Oliva, M. L., Dimopoulos, N., Magalhaes, M. R., Song, A. T. W., D'Albuquerque, L. A. C., Chiesi, S., Salerno, N. D., Mourao, P. H. O., Moreno, A., Linares, L., Almela, M., Rico, C. G., Rodrigo, E., Martinez, M. F., Falcone, M., Tumbarello, M., Strabelli, T. M. V., Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades (España), Red Española de Investigación en Patología Infecciosa, European Commission, Sociedad Andaluza de Trasplante de Órganos y Tejidos, and Ministerio de Ciencia e Innovación (España)

Subjects
Ertapenem, medicine.medical_specialty, Urinary system, UTI, Bacteremia, Bloodstream infection, BSI, Logistic regression, Extended-spectrum-b-lactamase-producing Enterobacterales, Meropenem, beta-Lactamases, Cohort Studies, chemistry.chemical_compound, Internal medicine, polycyclic compounds, medicine, Humans, Pharmacology (medical), Propensity Score, Kidney transplant, Retrospective Studies, Pharmacology, Urinary tract infection, business.industry, ESBL-E, Anti-Bacterial Agents, Kidney Transplantation, Urinary Tract Infections, bacterial infections and mycoses, medicine.disease, Infectious Diseases, chemistry, Propensity score matching, Cohort, business, medicine.drug, Cohort study
Abstract

REIPI/ESGICH/ESGBIS/INCREMENT-SOT Group., There are scarce data on the efficacy of ertapenem in the treatment of bacteremia due to extended-spectrum-beta-lactamase (ESBL)-producing Enterobacterales (ESBL-E) in kidney transplant (KT) recipients. We evaluated the association between treatment with ertapenem or meropenem and clinical cure in KT recipients with nonsevere bacteremic urinary tract infections (B-UTI) caused by ESBL-E. We performed a registered, retrospective, international (29 centers in 14 countries) cohort study (INCREMENT-SOT, NCT02852902). The association between targeted therapy with ertapenem versus meropenem and clinical cure at day 14 (the principal outcome) was studied by logistic regression. Propensity score matching and desirability of outcome ranking (DOOR) analyses were also performed. A total of 201 patients were included; only 1 patient (treated with meropenem) in the cohort died. Clinical cure at day 14 was reached in 45/100 (45%) and 51/101 (50.5%) of patients treated with ertapenem and meropenem, respectively (adjusted OR 1.29; 95% CI 0.51 to 3.22; P = 0.76); the propensity score-matched cohort included 55 pairs (adjusted OR for clinical cure at day 14, 1.18; 95% CI 0.43 to 3.29; P = 0.74). In this cohort, the proportion of cases treated with ertapenem with better DOOR than with meropenem was 49.7% (95% CI, 40.4 to 59.1%) when hospital stay was considered. It ranged from 59 to 67% in different scenarios of a modified (weights-based) DOOR sensitivity analysis when potential ecological advantage or cost was considered in addition to outcome. In conclusion, targeted therapy with ertapenem appears as effective as meropenem to treat nonsevere B-UTI due to ESBL-E in KT recipients and may have some advantages., This work was supported by Plan Nacional de I+D+i 2013‐2016 and Instituto de Salud Carlos III (ISCIII), Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001, RD16/0016/0002, RD16/0016/0008; RD16/0016/00010) and was cofinanced by the European Development Regional Fund “A way to achieve Europe,” Operative program Intelligent Growth 2014‐2020; ESCMID Study Group for Infections in Compromised Hosts (ESGICH grant to J.M.A.); Sociedad Andaluza de Trasplante de Órgano Sólido (SATOT grant to L.M.-M.); ESCMID Study Group for Bloodstream Infections and Sepsis (ESGBIS); and ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS). B.G.-G. (PI 18/01849) and E.P.-N. (PI 16/01631) have received research funds from the Spanish Ministry of Science and Innovation, ISCIII; M.F.-R. holds a research contract “Miguel Servet” (CP 18/00073) from the Spanish Ministry of Science and Innovation, ISCIII.

Published
2021

40. Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance

Author

Padilla, B., Muñoz, P., Guinea, J., Paño Pardo, J.R., García-Rodríguez, J., Cerrada, C.G., Fortún, J., Martín, P., Gómez, E., Ryan, P., Campelo, C., de los Santos Gil, I., Buendía, V., Gorricho, B.P., Alonso, M., Sanz, F.S., Aguado, J.M., Merino, P., González Romo, F., Gorgolas, M., Gadea, I., Losa, J.E., Delgado-Iribarren, A., Ramos, A., Romero, Y., Romero, I.S., Zaragoza, O., Cuenca-Estrella, M., Rodríguez-Baño, J., Suarez, A.I., Loza, A., Aller García, A.I., Martín-Mazuelos, E., Pérez de Pipaón, M.R., Garnacho, J., Ortiz, C., Chávez, M., Maroto, F.L., Salavert, M., Pemán, J., Blanquer, J., Navarro, D., Camarena, J.J., Zaragoza, R., Abril, V., Gimeno, C., Hernández, S., Ezpeleta, G., Bereciartua, E., Hernández Almaraz, J.L., Montejo, M., Rivas, R.A., Ayarza, R., Planes, A.M., Camps, I.R., Almirante, B., Mensa, J., Almela, M., Gurgui, M., Sánchez-Reus, F., Martínez-Montauti, J., Sierra, M., Horcajada, J.P., Sorli, L., Gómez, J., Gené, A., Urrea, M., Mularoni, A., Valerio, M., Díaz-Martín, A., Puchades, F., Fernández-Ruiz, M., Lora-Pablos, D., Zaragoza, Ó., and Puig-Asensio, M.

Published
2017
Full Text
View/download PDF

41. Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia

Author

Padilla, B., Muñoz, P., Guinea, J., Paño Pardo, J.R., García-Rodríguez, J., García Cerrada, C., Fortún, J., Martín, P., Gómez, E., Ryan, P., Campelo, C., de los Santos Gil, I., Buendía, V., Gorricho, B.P., Alonso, M., Sanz, F.S., Aguado, J.M., Merino, P., González Romo, F., Gorgolas, M., Gadea, I., Losa, J.E., Delgado-Iribarren, A., Ramos, A., Romero, Y., Sánchez Romero, I., Zaragoza, O., Cuenca-Estrella, M., Rodriguez-Baño, J., Isabel Suarez, A., Loza, A., Aller García, A.I., Martín-Mazuelos, E., Pérez de Pipaón, M.R., Garnacho, J., Ortiz, C., Chávez, M., Maroto, F.L., Salavert, M., Pemán, J., Blanquer, J., Navarro, D., Camarena, J.J., Zaragoza, R., Abril, V., Gimeno, C., Hernáez, S., Ezpeleta, G., Bereciartua, E., Hernández Almaraz, J.L., Montejo, M., Rivas, R.A., Ayarza, R., Planes, A.M., Camps, I.R., Almirante, B., Mensa, J., Almela, M., Gurgui, M., Sánchez-Reus, F., Martinez-Montauti, J., Sierra, M., Horcajada, J.P., Sorli, L., Gómez, J., Gené, A., Urrea, M., Valerio, M., Díaz-Martín, A., Puchades, F., Mularoni, A., Rueda, C., and Puig-Asensio, M.

Published
2017
Full Text
View/download PDF

45. Revisiting the epidemiology of bloodstream infections and healthcare-associated episodes: results from a multicentre prospective cohort in Spain (PRO-BAC Study)

Author

Perez-Crespo P, Lanz-Garcia J, Bravo-Ferrer J, Canton-Bulnes M, Dominguez A, Aguirre J, Reguera-Iglesias J, Jimenez E, Castillo C, Vallejo M, Ciordia T, Suarez J, Boix-Palop L, Pedragosa J, Saenz A, Blanco J, Galan-Sanchez F, Kindelan C, Jimenez A, Bahamonde-Carrasco A, Amat A, Garcia D, Rodriguez C, Molina I, Camacho I, Sanchez-Porto A, Garcia M, Carral B, de Lucas E, Lopez-Hernandez I, Rodriguez-Bano J, Lopez-Cortes L, and PROBAC REIPI GEIH-SEIMC SAEI Grp

Subjects
Epidemiology, Bacteraemia, Bloodstream infection, Aetiology, Healthcare-associated
Abstract

The epidemiology of bloodstream infections (BSIs) is dynamic as it depends on microbiological, host and healthcare system factors. The aim of this study was to update the information regarding the epidemiology of BSIs in Spain considering the type of acquisition. An observational, prospective cohort study in 26 Spanish hospitals from October 2016 through March 2017 including all episodes of BSI in adults was performed. Bivariate analyses stratified by type of acquisition were performed. Multivariate analyses were performed by logistic regression. Overall, 6345 BSI episodes were included; 2510 (39.8%) were community-acquired (CA), 1661 (26.3%) were healthcare-associated (HCA) and 2056 (32.6%) hospital-acquired (HA). The 30-day mortality rates were 11.6%, 19.5% and 22.0%, respectively. The median age of patients was 71 years (interquartile range 60-81 years) and 3656 (58.3%; 95% confidence interval 57.1-59.6%) occurred in males. The proportions according to patient sex varied according to age strata. Escherichia coli (43.8%), Klebsiella spp. (8.9%), Staphylococcus aureus (8.9%) and coagulase-negative staphylococci (7.4%) were the most frequent pathogens. Multivariate analyses confirmed important differences between CA and HCA episodes, but also between HCA and HA episodes, in demographics, underlying conditions and aetiology. In conclusion, we have updated the epidemiological information regarding patients' profiles, underlying conditions, frequency of acquisition types and aetiological agents of BSI in Spain. HCA is confirmed as a distinct type of acquisition. (C) 2021 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.

Published
2021

46. Propensity Score and Desirability of Outcome Ranking Analysis of Ertapenem for Treatment of Nonsevere Bacteremic Urinary Tract Infections Due to Extended-Spectrum-Beta-Lactamase-Producing Enterobacterales in Kidney Transplant Recipients

Author

Gutierrez-Gutierrez B, Perez-Nadales E, Perez-Galera S, Fernandez-Ruiz M, Carratala J, Oriol I, Cordero E, Lepe J, Tan B, Corbella L, Paul M, Natera A, David M, Montejo M, Iyer R, Pierrotti L, Merino E, Steinke S, Rana M, Munoz P, Mularoni A, van Delden C, Grossi P, Seminari E, Gunseren F, Lease E, Roilides E, Fortun J, Arslan H, Coussement J, Tufan Z, Pilmis B, Rizzi M, Loeches B, Eriksson B, Abdala E, Soldani F, Lowman W, Clemente W, Bodro M, Farinas M, Kazak E, Martinez-Martinez L, Aguado J, Torre-Cisneros J, Pascual A, Rodriguez-Bano J, and Investigators REIPI ESGICH ESGBIS

Subjects
kidney transplant, ertapenem, UTI, bloodstream infection, BSI, urinary tract infection, extended-spectrum-beta-lactamase-producing Enterobacterales, ESBL-E
Abstract

There are scarce data on the efficacy of ertapenem in the treatment of bacteremia due to extended-spectrum-beta-lactamase (ESBL)-producing Enterobacterales (ESBL-E) in kidney transplant (KT) recipients. We evaluated the association between treatment with ertapenem or meropenem and clinical cure in KT recipients with nonsevere bacteremic urinary tract infections (B-UTI) caused by ESBL-E. We performed a registered, retrospective, international (29 centers in 14 countries) cohort study (INCREMENT-SOT, NCT02852902). The association between targeted therapy with ertapenem versus meropenem and clinical cure at day 14 (the principal outcome) was studied by logistic regression. Propensity score matching and desirability of outcome ranking (DOOR) analyses were also performed. A total of 201 patients were included; only 1 patient (treated with meropenem) in the cohort died. Clinical cure at day 14 was reached in 45/100 (45%) and 51/101 (50.5%) of patients treated with ertapenem and meropenem, respectively (adjusted OR 1.29; 95% CI 0.51 to 3.22; P = 0.76); the propensity score-matched cohort included 55 pairs (adjusted OR for clinical cure at day 14, 1.18; 95% CI 0.43 to 3.29; P = 0.74). In this cohort, the proportion of cases treated with ertapenem with better DOOR than with meropenem was 49.7% (95% CI, 40.4 to 59.1%) when hospital stay was considered. It ranged from 59 to 67% in different scenarios of a modified (weights-based) DOOR sensitivity analysis when potential ecological advantage or cost was considered in addition to outcome. In conclusion, targeted therapy with ertapenem appears as effective as meropenem to treat nonsevere B-UTI due to ESBL-E in KT recipients and may have some advantages.

Published
2021

47. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score

Author

Berenguer, J, Borobia, AM, Ryan, P, Rodriguez-Bano, J, Bellon, JM, Jarrin, I, Carratala, J, Pachon, J, Carcas, AJ, Yllescas, M, Arribas, JR, López-Contreras J., Pascual, P., Pomar V., Rabella N., Benito N., Domingo P., Bonfill X., Mancebo J., and MARTIN VEGA, ALBERTO

Subjects
critical care, emergency medicine, respiratory infection, pneumonia, viral infection, clinical epidemiology
Abstract

Objective To develop and validate a prediction model of mortality in patients with COVID-19 attending hospital emergency rooms. Design Multivariable prognostic prediction model. Setting 127 Spanish hospitals. Participants Derivation (DC) and external validation (VC) cohorts were obtained from multicentre and single-centre databases, including 4035 and 2126 patients with confirmed COVID-19, respectively. Interventions Prognostic variables were identified using multivariable logistic regression. Main outcome measures 30-day mortality. Results Patients' characteristics in the DC and VC were median age 70 and 61 years, male sex 61.0% and 47.9%, median time from onset of symptoms to admission 5 and 8 days, and 30-day mortality 26.6% and 15.5%, respectively. Age, low age-adjusted saturation of oxygen, neutrophil-to-lymphocyte ratio, estimated glomerular filtration rate by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, dyspnoea and sex were the strongest predictors of mortality. Calibration and discrimination were satisfactory with an area under the receiver operating characteristic curve with a 95% CI for prediction of 30-day mortality of 0.822 (0.806-0.837) in the DC and 0.845 (0.819-0.870) in the VC. A simplified score system ranging from 0 to 30 to predict 30-day mortality was also developed. The risk was considered to be low with 0-2 points (0%-2.1%), moderate with 3-5 (4.7%-6.3%), high with 6-8 (10.6%-19.5%) and very high with 9-30 (27.7%-100%). Conclusions A simple prediction score, based on readily available clinical and laboratory data, provides a useful tool to predict 30-day mortality probability with a high degree of accuracy among hospitalised patients with COVID-19.

Published
2021

48. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Author

Rodriguez-Bano J, Pachon J, Carratala J, Ryan P, Jarrin I, Yllescas M, Arribas J, Berenguer J, SAM-COVID Study Group, and VELA S

Abstract

OBJECTIVES: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. METHODS: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). RESULTS: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p

Published
2021

49. Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score–derived analysis of a population-based, multicentre prospective cohort

Author

Padilla, B., Muñoz, P., Guinea, J., Paño Pardo, J.R., García-Rodríguez, J., García Cerrada, C., Fortún, J., Martín, P., Gómez, E., Ryan, P., Campelo, C., de los Santos Gil, I., Buendía, V., Pérez Gorricho, B., Alonso, M., Sanz Sanz, F., María Aguado, J., Merino, P., González Romo, F., Gorgolas, M., Gadea, I., Losa, J.E., Delgado-Iribarren, A., Ramos, A., Romero, Y., Sánchez Romero, I., Zaragoza, O., Cuenca-Estrella, M., Rodríguez-Baño, J., Suarez, A.I., Loza, A., Aller García, A.I., Martín-Mazuelos, E., Pérez de Pipaón, M.R., Garnacho, J., Ortiz, C., Chávez, M., Maroto, F.L., Salavert, M., Pemán, J., Blanquer, J., Navarro, D., Camarena, J.J., Zaragoza, R., Abril, V., Gimeno, C., Hernáez, S., Ezpeleta, G., Bereciartua, E., Hernández Almaraz, J.L., Montejo, M., Rivas, R.A., Ayarza, R., Planes, A.M., Ruiz Camps, I., Almirante, B., Mensa, J., Almela, M., Gurgui, M., Sánchez-Reus, F., Martinez-Montauti, J., Sierra, M., Horcajada, J.P., Sorli, L., Gómez, J., Gené, A., Urrea, M., Valerio, M., Díaz-Martín, A., Puchades, F., Mularoni, A., López-Cortés, L.E., Garnacho-Montero, J., Puig-Asensio, M., and Ruiz-Camps, I.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results